Safety Study to Assess the FEasibility of Use of the TRYTON Bifurcation Coronary Stent System (SAFE-TRY)

Inclusion Criteria: General Inclusion Criteria * Candidate for percutaneous coronary intervention \& emergent coronary artery bypass graft surgery * Clinical evidence of ischemic heart disease or a positive functional study * Female patients of childbearing potential has negative pregnancy test within 7 days before trial procedure * Patient or patient's legal representative provided written informed consent * Patient agrees to comply with follow-up evaluations Angiographic Inclusion Criteria * Target lesion in a single de novo true bifurcation lesion (Medina classification Type 1.1.1; 1.0.1; 0.1.1; 0.0.1) involving a native coronary artery with reference vessel diameter for the proximal main of 2.5 - 5.0 mm, distal main of 2.5 - 5.0 mm, \& side branch RVD of 2.5 - 3.5 mm * Target lesion in main vessel has stenosis of \> 50% and \<100% * Syntax score \< 32 Exclusion Criteria: General Exclusion Criteria * Known hypersensitivity/contraindication to aspirin, heparin or bivalirudin, clopidogrel or ticlopidine, cobalt, nickel, chromium, molybdenum, or sensitivity to contrast media, which can't be adequately pre-medicated * Platelet count \<100,000 cells/mm³ or \>700,000 cells/mm³, or a white blood cell (WBC) count \<3,000 cells/mm³ within 7 days prior to index procedure * Serum creatinine level \>170 micromol/L within 7 days prior to index procedure * Evidence of acute MI within 72 hours of intended trial procedure (defined as: QWMI or NQWMI having CK enzymes \>2X laboratory upper limit of normal in the presence of a confirming cardiac specific biomarker (Troponin I or T) * Previous stenting anywhere in target vessel * Percutaneous coronary intervention (PCI) of non-target vessel within 30 days prior to procedure that results in any MAC(C)E event. If non target vessel stent is implanted within 72 hours prior to index procedure, 2 post procedural serial CK or CK-MB measurements must be below investigational site's upper limit of normal * PCI of non-target vessel within 24 hours prior to procedure * Planned PCI of the target vessel within 6 months post-procedure * During index procedure, target lesion requires treatment with device other than PTCA or cutting balloon prior to stent placement * Documented left ventricular ejection fraction (LVEF) \<30% at most recent evaluation * History of stroke or transient ischemic attack (TIA) within prior 6 months * Active peptic ulcer or upper gastrointestinal (GI) bleeding within prior 6 months * History of bleeding diathesis or coagulopathy or will refuse blood transfusions * Concurrent medical condition with life expectancy \<12 months * Currently participating in investigational drug or device trial that's not completed the primary endpoint or that clinically interferes with current trial endpoints; or requires coronary angiography, IVUS or other coronary artery imaging procedures. Angiographic Exclusion Criteria * Target lesion located in native vessel with saphenous vein graft or left/right internal mammary artery (LIMA/RIMA) bypass * Target lesion has any of following characteristics: * Severely calcified * Evidence of thrombus * Syntax score ≥33